Rare Form: GSK, NEA Back Orphan Disease Venture Fund
This article was originally published in Start Up
A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.
You may also be interested in...
The Dutch biotech raised $78 million in an initial public offering, peaking investors’ interest with a breakthrough designation for its lead drug candidate, partnered with GSK.
With Epizyme as a top performing biotech IPO and bluebird bio primed to go out soon, investor appetite would seem whetted for early stage biotechs on the public market. With improving overall IPO performance, these returns could again become meaningful for more than a few life science VCs.
The health care consultancy released a report that shows the rapid growth of the orphan drug sector as companies take advantage of incentives. Orphan oncologic drugs dominate the market, and Novartis is slated to lead in orphan sales by 2018.